Drugs / ID-085
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03913000 | Apr → Aug 2019 | impaired renal function disease | Idorsia Pharmaceuticals Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT03372629 | Jan → Dec 2018 | — | Idorsia Pharmaceuticals Ltd. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ID-085 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03372629 ↗ |
| Route | Oral | “Hard gelatin capsules for oral administration formulated in strengths of 10 mg, 100 mg, and 200 mg” NCT03372629 ↗ |